For the development of molecular markers for patient stratification in clinical trials testing the efficacy of PI3K pathway inhibitors, it is crucial to take into account the observations that in some tumor types, either PIK3CA activating mutations or PTEN loss of function are predictors of sensitivity, whereas in other tumor types, both predict sensitivity to these agents (Table 2). This evidence concerns the gene PIK3CA and neoplasm.